Rune Labs

Rune Labs monetizes through two channels. It deploys StrivePD as a care delivery ecosystem for clinicians and patients. It also licenses de-identified, longitudinal real-world datasets generated by that ecosystem to life-sciences companies for clinical trial support, real-world evidence, and commercial therapy adoption programs.

The company states it is expanding into other neurodegenerative diseases where the same data-collection and clinical-workflow approach applies. Named target conditions on its website include Multiple Sclerosis (MS), Obsessive-Compulsive Disorder (OCD), and Essential Tremor.

Apple Watch serves as a continuous passive data-collection device within the StrivePD ecosystem. It captures movement and symptom data from patients, which is combined with medication-tracking inputs from a companion patient app. The combined data stream feeds clinician dashboards and the company's real-world evidence datasets.

Rune Labs maintains a dual constituency. On the care-delivery side, it partners with clinicians and patients who use StrivePD. On the data side, it partners with life-sciences companies and academic research facilities, providing access to its network of engaged patients and longitudinal datasets to expedite neurology therapy development.

Most CROs or recruitment tools are transaction-based or episodic. Rune Labs embeds software directly into the ongoing care pathway for a chronic disease. This continuous engagement generates a flowing real-world dataset over years, which the company uses to power synthetic control cohorts and enriched recruitment — making the data asset more durable than a one-off trial service.